Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 674039, 7 pages
http://dx.doi.org/10.1155/2015/674039
Research Article

Genetic Variations in Inflammatory Response Genes and Their Association with the Risk of Prostate Cancer

Department of Urology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

Received 1 April 2015; Revised 25 May 2015; Accepted 10 June 2015

Academic Editor: Sabine Rohrmann

Copyright © 2015 Xin Cui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, M. Ervik et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, International Agency for Research on Cancer, Lyon, France, 2013, http://globocan.iarc.fr.
  2. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” Ca: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Zhang, S. Wu, L.-R. Guo, and X.-J. Zhao, “Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China,” Asian Journal of Andrology, vol. 11, no. 1, pp. 9–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. P. D. Baade, D. R. Youlden, S. M. Cramb, J. Dunn, and R. A. Gardiner, “Epidemiology of prostate cancer in the Asia-Pacific region,” Prostate International, vol. 1, no. 2, pp. 47–58, 2013. View at Google Scholar
  5. M. F. Leitzmann and S. Rohrmann, “Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates,” Clinical Epidemiology, vol. 4, no. 1, pp. 1–11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. O. N. Kryvenko, M. Jankowski, D. A. Chitale et al., “Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer,” Modern Pathology, vol. 25, no. 7, pp. 1023–1032, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. M. M. Shen and C. Abate-Shen, “Molecular genetics of prostate cancer: new prospects for old challenges,” Genes and Development, vol. 24, no. 18, pp. 1967–2000, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. De Marzo, E. A. Platz, S. Sutcliffe et al., “Inflammation in prostate carcinogenesis,” Nature Reviews Cancer, vol. 7, no. 4, pp. 256–269, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. J. Alvarez-Cubero, M. Saiz, L. J. Martinez-Gonzalez, J. C. Alvarez, J. A. Lorente, and J. M. Cozar, “Genetic analysis of the principal genes related to prostate cancer: a review,” Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 8, pp. 1419–1429, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. C. Tan, M. S. M. Suzairi, A. A. A. Aizat et al., “Gender-specific association of NFKBIA promoter polymorphisms with the risk of sporadic colorectal cancer,” Medical Oncology, vol. 30, no. 4, article 693, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. X. Li, S.-J. Wang, S. C. Tan et al., “The A55T and K153R polymorphisms of MSTN gene are associated with the strength training-induced muscle hypertrophy among Han Chinese men,” Journal of Sports Sciences, vol. 32, no. 9, pp. 883–891, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. M. S. Mohd Suzairi, S. C. Tan, A. A. Ahmad Aizat et al., “The functional -94 insertion/deletion ATTG polymorphism in the promoter region of NFKB1 gene increases the risk of sporadic colorectal cancer,” Cancer Epidemiology, vol. 37, no. 5, pp. 634–638, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. T. I. Kopp, S. Friis, J. Christensen, A. Tjønneland, and U. Vogel, “Polymorphisms in genes related to inflammation, NSAID use, and the risk of prostate cancer among Danish men,” Cancer Genetics, vol. 206, no. 7-8, pp. 266–278, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Kazma, J. A. Mefford, I. Cheng et al., “Association of the innate immunity and inflammation pathway with advanced prostate cancer risk,” PLoS ONE, vol. 7, no. 12, Article ID e51680, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Ianni, E. Porcellini, I. Carbone et al., “Genetic factors regulating inflammation and DNA methylation associated with prostate cancer,” Prostate Cancer and Prostatic Diseases, vol. 16, no. 1, pp. 56–60, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. E. M. Kwon, C. A. Salinas, S. Kolb et al., “Genetic polymorphisms in inflammation pathway genes and prostate cancer risk,” Cancer Epidemiology, Biomarkers & Prevention, vol. 20, no. 5, pp. 923–933, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Martin, “Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components,” Mutation Research, vol. 690, no. 1-2, pp. 57–63, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. S. Deeb, L. Fajas, M. Nemoto et al., “A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Paltoo, K. Woodson, P. Taylor, D. Albanes, J. Virtamo, and J. Tangrea, “Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study,” Cancer Letters, vol. 191, no. 1, pp. 67–74, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Zmuda, F. Modugno, J. L. Weissfeld et al., “Peroxisome proliferator-activated receptor-γ polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction,” Oncology, vol. 70, no. 3, pp. 185–189, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. A. S. Karban, T. Okazaki, C. I. M. Panhuysen et al., “Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis,” Human Molecular Genetics, vol. 13, no. 1, pp. 35–45, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Zhang, Q. Wei, X. Li et al., “A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer,” Cancer Genetics and Cytogenetics, vol. 191, no. 2, pp. 73–77, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. C.-W. Cheng, J.-L. Su, C.-W. Lin et al., “Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features,” PLoS ONE, vol. 8, no. 2, Article ID e56130, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. C.-W. Lin, Y.-S. Hsieh, C.-H. Hsin et al., “Effects of NFKB1 and NFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer,” PLoS ONE, vol. 7, no. 4, Article ID e35078, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Umar, R. Upadhyay, S. Kumar, U. C. Ghoshal, and B. Mittal, “Association of common polymorphisms in TNFA, NFkB1 and NFKBIA with risk and prognosis of esophageal squamous cell carcinoma,” PLoS ONE, vol. 8, no. 12, Article ID e81999, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Shi, N. L. A. Misso, D. L. Duffy et al., “Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atopy,” European Respiratory Journal, vol. 26, no. 2, pp. 249–256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. H. S. de Vries, R. H. M. te Morsche, M. G. H. van Oijen, I. D. Nagtegaal, W. H. M. Peters, and D. J. de Jong, “The functional -765GC polymorphism of the COX-2 gene may reduce the risk of developing crohn's disease,” PLoS ONE, vol. 5, no. 11, Article ID e15011, 2010. View at Publisher · View at Google Scholar
  28. S. Sugie, H. Tsukino, S. Mukai et al., “Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese Men,” Tumor Biology, vol. 35, no. 3, pp. 2717–2721, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. H.-C. Wu, C.-H. Chang, H.-L. Ke et al., “Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in Taiwan,” Anticancer Research, vol. 31, no. 1, pp. 221–225, 2011. View at Google Scholar · View at Scopus
  30. I. Cheng, X. Liu, S. J. Plummer, L. M. Krumroy, G. Casey, and J. S. Witte, “COX2 genetic variation, NSAIDs, and advanced prostate cancer risk,” British Journal of Cancer, vol. 97, no. 4, pp. 557–561, 2007. View at Publisher · View at Google Scholar · View at Scopus